FDA Action Update, July 2026: Approval, Acceptances, and Advisory Committee Vote

The FDA was busy in July 2026, making a number of decisions on potential new therapeutic agents, including a formulation approval, acceptances of new drug applications (NDAs), and voting at an advisory committee meeting.

With all the treatments that have progressed through the pipeline of clinical development, the NeurologyLive^® team has been hard at work covering all the agency movements to make sure you are up to date on the latest news in neurology. To give you a chance to catch up on any of the headlines you may have missed, we’ve compiled all the updates here. The coverage includes the latest FDA approvals, new designations, submissions, resubmissions, and clinical trial initiations and holds.

FDA Approves At-Home Starting Dose for Lecanemab, Marking First Subcutaneous Initiation Option for Alzheimer Disease Treatment

In the middle of the month, on July 13, 2026, the FDA approved a subcutaneous starting dose regimen for lecanemab-irmb (Leqembi; Eisai/Biogen), allowing patients with early Alzheimer disease (AD) to initiate treatment at home via weekly self-injection for the first time. The decision marks a meaningful shift in how the therapy can be delivered, removing the prior requirement that patients complete 18 months of intravenous infusions before becoming eligible for at-home subcutaneous dosing.¹

The approval builds on more than 2 years of regulatory and formulation development for lecanemab. The drug first received FDA accelerated approval in January 2023, followed by traditional approval in July 2023, in its intravenous formulation at 10 mg/kg given every 2 weeks, based on data from the phase 3 Clarity AD trial (NCT03887455) in 1795 patients with confirmed amyloid pathology and MCI or mild dementia. That trial showed lecanemab slowed clinical decline by 27% versus placebo on the CDR-SB scale over 18 months. Patients were then limited to IV treatment throughout.

"What I find most encouraging about the approval is that this is the first time patients can start anti-amyloid Alzheimer's treatment from home. That's a real shift in how care can be delivered, not just a convenience upgrade. Alzheimer's care is moving toward combination therapy, much as cancer treatment did. But that only works if the treatments are practical enough for patients to stay on long-term,” Laura Nisenbaum, PhD, interim chief science officer at the Alzheimer's Drug Discovery Foundation (ADDF), told NeurologyLive^®.

FDA Accepts NDA for Apnimed’s AD109 for the Treatment of Obstructive Sleep Apnea

A few days later, on July 15, 2026, the FDA accepted for review Apnimed's new drug application (NDA) for AD109 (aroxybutynin 2.3 mg/atomoxetine 75 mg), an investigational once-nightly oral combination therapy designed to target the neuromuscular basis of upper airway collapse in adults with obstructive sleep apnea (OSA). The agency has assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027.²

The NDA is supported by data from 2 positive phase 3 randomized, double-blind, placebo-controlled trials, dubbed SynAIRgy (NCT05813275) and LunAIRo (NCT05811247), which both met their primary end point compared with placebo among adults with mild-to-severe OSA. Designed for use across varying levels of disease severity, AD109 offers the promise of a safe, effective, and more user-friendly alternative to current OSA treatments, which are often invasive or difficult for patients to tolerate.

"The FDA acceptance of our NDA is an important milestone for Apnimed as we advance toward our goal of expanding treatment options for people with OSA who continue to need more accessible solutions," Kevin Lind, chief executive officer at Apnimed, said in a statement.² "The NDA is supported by a clinical data package that reflects years of scientific innovation focused on a major unmet need. We believe AD109 has the potential to offer an important new treatment option for adults with OSA, if approved, and we look forward to engaging with the FDA during its review."

FDA Accepts NDA for Axsome Therapeutics’ AXS-12 for the Treatment of Cataplexy in Narcolepsy

On the same day, on July 15, 2026, the FDA accepted for filing Axsome Therapeutics' NDA for AXS-12 (reboxetine), an investigational selective norepinephrine reuptake inhibitor, as a potential treatment for cataplexy in narcolepsy. The agency has assigned a PDUFA target action date of May 1, 2027, and does not currently plan to convene an advisory committee to review the application.³

The regulatory milestone marks the entry of a novel therapeutic approach into clinical development at a time when most approved MS therapies primarily target inflammatory disease activity rather than repair of existing central nervous system (CNS) damage. Although disease-modifying therapies (DMTs) have substantially reduced relapse rates and MRI activity in relapsing forms of MS, disability progression remains an important unmet need, particularly in progressive disease, where neurodegeneration and incomplete remyelination contribute to long-term functional decline.

“FDA IND clearance is an important milestone for our PTD802 program, and a step further toward our ultimate goal of providing an effective treatment for neurological diseases associated with demyelination,” Fraser Murray, PhD, CEO of Pheno Therapeutics, said in a statement.⁴ “As the first company to gain approval to begin clinical trials for a selective GPR17 antagonist, we are proud to be leading the way, and believe this approach has the potential to offer real patient benefit, in MS and beyond.”

FDA Accepts BLA for Z-Rostudirsen in DMD, Sets January PDUFA Date

Almost a week later, on July 20, 2026, the FDA accepted for review the biologics license application (BLA) for zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) for Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The agency granted priority review and set a PDUFA date of January 21, 2027. Dyne Therapeutics continues to expect a potential U.S. launch in the first quarter of 2027, assuming approval on the anticipated timeline.⁵

The submission seeks accelerated approval based on dystrophin as a surrogate end point, a pathway already established for other exon-skipping therapies in DMD. The BLA is built on the registrational expansion cohort (REC) of the global phase 1/2 DELIVER trial (NCT05524883), which enrolled 32 ambulatory and nonambulatory boys with DMD aged 4 to 16 years with mutations amenable to exon 51 skipping; 24 were randomly assigned to z-rostudirsen 20 mg/kg every 4 weeks and 8 to placebo.

“This milestone represents significant progress toward our goal of delivering functional improvement for those living with DMD amenable to exon 51 skipping,” John Cox, president and CEO of Dyne, said in a statement.⁵ “With z-rostudirsen, we set out to advance the treatment paradigm in DMD by combining a robust increase in near-full-length dystrophin with broad delivery to relevant tissues.”

FDA Advisory Committee Votes Against Deramiocel for DMD Cardiomyopathy

At the end of the month, on July 29, 2026, The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 9 to 3, with no abstentions, that the available evidence does not provide substantial evidence of effectiveness to recommend approval for deramiocel in treating cardiomyopathy in patients with Duchenne muscular dystrophy (DMD).⁶ The vote is nonbinding, but it signals a difficult path ahead for Capricor Therapeutics' biologics license application (BLA) ahead of the FDA's August 22, 2026, PDUFA target action date.

Members who voted no generally cited concerns about the stability of the statistical results, saying that outcomes on the left ventricular ejection fraction (LVEF) end point, and to a lesser extent the upper-limb endpoint, appeared highly sensitive to how missing data were handled and which analytic assumptions were applied. Several said they had not seen evidence that LVEF, as measured in the trial, functions as a validated surrogate for clinical benefit in this population, and some noted that earlier versions of the sponsor's own statistical analysis had not met the prespecified endpoint.

A few members also raised questions about a potential safety signal related to increases in left ventricular volume that they said warranted further evaluation. Several no-voting members emphasized the significant unmet medical need in DMD cardiomyopathy and characterized their vote as reflecting the narrow scope of the question posed rather than a broader judgment on the therapy's underlying scientific rationale.

Click here to view the latest of our FDA news coverage.

REFERENCES
1. FDA approves first at-home starting dose for Alzheimer's disease treatment. News release. US Food and Drug Administration. July 13, 2026. Accessed July 31, 2026. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-home-starting-dose-alzheimers-disease-treatment
2. Apnimed Announces FDA Acceptance of New Drug Application for AD109, An Investigational Oral Pill to Treat Adults with Obstructive Sleep Apnea (OSA). News release. July 14, 2026. Accessed July 31, 2026. https://apnimed.com/article/apnimed-announces-fda-acceptance-of-new-drug-application-for-ad109-an-investigational-oral-pill-to-treat-adults-with-obstructive-sleep-apnea/
3. Axsome Therapeutics announces FDA acceptance of new drug application for AXS-12 for the treatment of cataplexy in narcolepsy. News release. Axsome Therapeutics. July 15, 2026. Accessed July 31, 2026. https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-fda-acceptance-new-drug-1
4. Axsome Therapeutics announces AXS-12 achieves primary endpoint in ENCORE long-term phase 3 trial in narcolepsy. News release. Axsome Therapeutics. November 26, 2024. Accessed July 31, 2026. https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-axs-12-achieves-primary-endpoint-1
5. Dyne Therapeutics announces U.S. FDA acceptance of biologics license application (BLA) for z-rostudirsen in exon 51 Duchenne muscular dystrophy (DMD). News release. Dyne Therapeutics. July 20, 2026. Accessed July 31, 2026. https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-us-fda-acceptance-biologics-license
6. Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket. Federal Register. June 29, 2026. Accessed July 31, 2026. https://www.federalregister.gov/documents/2026/06/29/2026-13096/cellular-tissue-and-gene-therapies-advisory-committee-notice-of-meeting-establishment-of-a-public